Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 24, 2023

BUY
$0.22 - $0.5 $23,037 - $52,358
104,717 Added 316.91%
137,760 $41,000
Q4 2022

Feb 08, 2023

BUY
$0.41 - $1.1 $9,119 - $24,467
22,243 Added 205.95%
33,043 $15,000
Q3 2022

Oct 25, 2022

BUY
$0.57 - $1.77 $113 - $354
200 Added 1.89%
10,800 $9,000
Q2 2022

Aug 12, 2022

SELL
$0.85 - $1.41 $1,623 - $2,693
-1,910 Reduced 15.27%
10,600 $10,000
Q1 2022

May 11, 2022

SELL
$1.16 - $2.5 $5,932 - $12,785
-5,114 Reduced 29.02%
12,510 $17,000
Q4 2021

Feb 08, 2022

SELL
$2.46 - $8.74 $176,532 - $627,191
-71,761 Reduced 80.28%
17,624 $43,000
Q3 2021

Nov 02, 2021

BUY
$5.1 - $9.39 $240,781 - $443,320
47,212 Added 111.95%
89,385 $763,000
Q2 2021

Aug 11, 2021

BUY
$3.95 - $6.88 $166,583 - $290,150
42,173 New
42,173 $270,000

Others Institutions Holding PAVM

# of Institutions
1
Shares Held
2.24M
Call Options Held
0
Put Options Held
0

About PAVmed Inc.


  • Ticker PAVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 90,999,104
  • Market Cap $74.6M
  • Description
  • PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted ne...
More about PAVM
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.